Gastrointestinal Stromal Tumors
130
21
27
66
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
29 trials with published results (22%)
Research Maturity
66 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
10.0%
13 terminated out of 130 trials
83.5%
-3.0% vs benchmark
16%
21 trials in Phase 3/4
44%
29 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (130)
Integrated Cancer Repository for Cancer Research
Development of a Multimodal AI System for GIST Management
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Imatinib TDM in GIST
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Observational Registry Data on GIST Patients
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)